ResearcherNanjing University of Chinese MedicineNo recent work listed

Weikang Kong

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper

Papers 1

Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. Co-author DOI 10.1016/j.ejphar.2023.175703 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Peng Cao · 1 shared paper, 2023 · strength 0.17
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗
Xueting Cai · 1 shared paper, 2023 · strength 0.17
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗
Wenjing Ji · 1 shared paper, 2023 · strength 0.17
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.